AIM
OREX

Advantage Investment Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Advantage Investment Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-140
Closed -$7K – 943
2015
Q2 		$7K Hold
140
– – ﹤0.01% 662
2015
Q1 		$11K Hold
140
– – 0.01% 576
2014
Q4 		$8K Buy
+140
New +$7.03K 0.01% 566

Other funds holding OREX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advantage Investment Management's OREX Position: Q3 2015 in Review

Advantage Investment Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 140 shares — an estimated $7K sold.

Advantage Investment Management first reported a position in OREX in Q4 2014 and held it in 3 quarters. The position peaked at $11K in Q1 2015. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

  • Advantage Investment Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Advantage Investment Management sold 140 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $7K.
  • Advantage Investment Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Advantage Investment Management's Orexigen Therapeutics, Inc. position peaked at $11K in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Advantage Investment Management's 13F filing for Q3 2015, filed 27 Mar 2017.